This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines
2. Signed and dated informed consent form
3. Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of \> 6 months
Exclusion Criteria:
1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
2. Intestinal perforation, complete intestinal obstruction
3. Pregnant women and women who may be pregnant, women who are breastfeeding.
4. Non-compliant person
Primary outcome measure(s)
Evaluation the responses to immunotherapy of pancreatic cancer — up to about 10 weeks The value of 68Ga-grazytracer PET in monitoring responses to immunotherapy of pancreatic cancer
Standardized uptake value(SUV) — up to about 10 weeks SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Target-to-background ratio(TBR) — up to about 10 weeks 68Ga-grazytracer uptake ratio of tumor lesions to mediastinum and liver blood pool on PET/CT images.
Trial sites (1)
Facility
City
Region
Status
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.